Delivers Illumina's flagship oncology products on its most powerful sequencers to enable comprehensive genomic profiling at greater scale and at lower overall costs for customers SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced it has expanded its oncology menu for NovaSeqTM X Series customers.
The company began offering the newly verified high-throughput version of TruSightTM Oncology 500 (TSO 500 HT), and the latest version of its distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), in recent months. These assays enable labs to confidently expand oncology testing research of tissue and liquid biopsy samples, with new transformative sequencing economics, faster sequencing run times, and broader batch sizes on the NovaSeq X Series for the first time..